George R Blumenschein
Overview
Explore the profile of George R Blumenschein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2025 Feb;
639(8054):E19.
PMID: 40016449
No abstract available.
2.
Negrao M, Paula A, Molkentine D, Hover L, Nilsson M, Vokes N, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39804166
Background: KRAS inhibitors are revolutionizing the treatment of NSCLC, but clinico-genomic determinants of treatment efficacy warrant continued exploration. Methods: Patients with advanced KRASG12C-mutant NSCLC treated with adagrasib (KRYSTAL-1-NCT03785249) were included...
3.
Zhou N, Leung C, William Jr W, Weissferdt A, Pataer A, Godoy M, et al.
J Immunother Cancer
. 2024 Oct;
12(10.
PMID: 39448200
Background: Neoadjuvant immune checkpoint inhibitors (ICIs) have improved survival outcomes compared with chemotherapy in resectable non-small cell lung cancer (NSCLC). However, the impact of actionable genomic alterations (AGAs) on the...
4.
Skoulidis F, Araujo H, Do M, Qian Y, Sun X, Cobo A, et al.
Nature
. 2024 Oct;
635(8038):462-471.
PMID: 39385035
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) with CTLA4 inhibitors and PD-1 or PD-L1 inhibitors (hereafter, PD-(L)1 inhibitors) is associated with higher rates of...
5.
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, et al.
Nat Commun
. 2024 Jul;
15(1):5621.
PMID: 38965214
No abstract available.
6.
Luke J, Patel M, Blumenschein G, Hamilton E, Chmielowski B, Ulahannan S, et al.
Nat Med
. 2023 Oct;
29(11):2814-2824.
PMID: 37857711
Tebotelimab, a bispecific PD-1×LAG-3 DART molecule that blocks both PD-1 and LAG-3, was investigated for clinical safety and activity in a phase 1 dose-escalation and cohort-expansion clinical trial in patients...
7.
Weidhaas J, Hu C, Komaki R, Masters G, Blumenschein G, Chang J, et al.
Cancer Res Commun
. 2023 Sep;
3(10):2074-2081.
PMID: 37728512
Purpose: RTOG 0617 was a phase III randomized trial for patients with unresectable stage IIIA/IIIB non-small cell lung cancer comparing standard-dose (60 Gy) versus high-dose (74 Gy) radiotherapy and chemotherapy,...
8.
Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, et al.
J Immunother Cancer
. 2023 Jul;
11(7).
PMID: 37402581
Background: Up to 20% of patients with non-small cell lung cancer (NSCLC) develop brain metastasis (BM), for which the current standard of care is radiation therapy with or without surgery....
9.
Altan M, Tu J, Milton D, Yilmaz B, Tian Y, Fossella F, et al.
Cancer
. 2023 May;
129(17):2685-2693.
PMID: 37129197
Background: In lung cancer, overexpression of nuclear export proteins can result in inactivation of critical tumor suppressor proteins and cell-cycle regulators. Selective suppression of nuclear export proteins has immunomodulatory activities....
10.
Negrao M, Araujo H, Lamberti G, Cooper A, Akhave N, Zhou T, et al.
Cancer Discov
. 2023 Apr;
13(7):1556-1571.
PMID: 37068173
Significance: In this work, we identify co-occurring genomic alterations in KEAP1, SMARCA4, and CDKN2A as independent determinants of poor clinical outcomes with KRASG12Ci monotherapy in advanced NSCLC, and we propose...